Atabay Chemical Industry

What Atabay Chemical Industry does

Atabay Chemical Industry (Atabay Kimya Sanayi Ticaret A.Ş.) is an Istanbul-based, family-owned pharmaceutical manufacturer founded in 1939 and now in its third generation of stewardship. The company produces active pharmaceutical ingredients (APIs) and finished pharmaceutical products across 470 product licenses, and is the only producer of P-aminophenol and paracetamol in the EMEA region, operating 3,500 tons of annual paracetamol capacity and 250 million boxes/year of finished-dose capacity. It is the 6th-largest pharmaceutical manufacturer in Turkey by unit volume and exports to 67 countries through 47 distributors.

The company's technology base is rooted in synthetic organic chemistry — it holds patented processes for paracetamol, Favipiravir, and Ruscus aculeatus — and it operates manufacturing facilities certified to EU GMP, Canada GMP, Turkish Ministry of Health GMP, and is qualified as a supplier by WHO and UNICEF. Through its Atabay BIO subsidiary (established 2019), Atabay has extended into biosimilars and vaccines, and in 2024 launched Neoven, its first domestically developed herbal medicine. It employs approximately 1,149 people (37% women), with a workforce that has scaled into the 1,200+ range.

Atabay's revenue model combines B2B API supply to international pharmaceutical companies, branded and generic finished-dose sales in Turkey and export markets, contract manufacturing for third parties, and episodic public-sector procurement (notably during the COVID-19 pandemic for Favipiravir). The distribution model relies on 47 distributors serving 67 countries, with regulated-market access unlocked by the 2020 EU GMP and Canada GMP certifications. Atabay does not publicly disclose revenue, and the absence of disclosed financials is itself a feature of its private, family-controlled structure.

Name

Atabay Chemical Industry

Legal name

Atabay Kimya Sanayi Ticaret A.Ş.

Website

https://atabay.com

Company type

Private

Founded year

1939

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Atabay Chemical Industry is a third-generation, family-owned Turkish pharmaceutical manufacturer (founded 1939) producing paracetamol and other APIs plus finished-dose medicines across 470 licenses, serving 67 countries via 47 distributors and operating the only P-aminophenol and paracetamol facility in EMEA.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Chemical Manufacturing (325), Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Active pharmaceutical ingredients
• Finished dosage pharmaceuticals
• Biotechnology vaccine production
• Contract pharmaceutical manufacturing
• Standardized herbal extracts

Headquarters

HQ city

Istanbul

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Human Pharmaceuticals (Beşeri İlaçlar): Finished dosage form pharmaceutical products including analgesics, antipyretics, antibiotics, anticoagulants, and antiviral medications sold through pharmacy and hospital channels
2. Active Pharmaceutical Ingredients (API): Manufacturing and export of pharmaceutical raw materials including paracetamol, oseltamivir, and acetylcysteine to pharmaceutical companies worldwide
3. Veterinary Products: Veterinary pharmaceutical products
4. Agricultural Chemicals: Agricultural pharmaceutical products
5. Contract Manufacturing: Third-party manufacturing services (fason üretim)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

Atabay Chemical Industry manufactures and markets pharmaceutical products, including active pharmaceutical ingredients (APIs) such as paracetamol, oseltamivir, and acetylcysteine, as well as finished dosage form medicines in tablets, capsules, syrups, sterile injectables, and suspensions. The company also operates a biotechnology division (Atabay BIO) for biosimilars and vaccines, produces standardized herbal extracts, and provides contract manufacturing services from GMP-certified facilities in Gebze and Acıbadem.

Product overview

Atabay Chemical Industry is a 87-year-old Turkish pharmaceutical company offering an integrated portfolio spanning active pharmaceutical ingredient (API) synthesis, finished dosage form pharmaceuticals, biotechnology products, and standardized herbal extracts. The core offerings include: (1) Chemical APIs - notably paracetamol, oseltamivir, and acetylcysteine where Atabay is the sole European manufacturer; (2) Atabay BIO division for biosimilars and vaccines; (3) Finished pharmaceutical products in tablets, capsules, syrups, sterile injectables, and suspensions with 250 million box annual capacity; (4) Neoven 225 mg Kapsül - Turkey's first 100% domestic seed-to-shelf herbal medicine; (5) Contract manufacturing services. The company operates GMP-certified Gebze and Acıbadem facilities and exports to 67 countries across five continents.

Differentiator

Problem solved

Functional benefit

Brands

• Neoven 225 mg Kapsül: Turkey's first 100% domestic 'seed-to-shelf' herbal medicine for chronic venous insufficiency and hemorrhoidal disease treatment.

Products and services

• Active Pharmaceutical Ingredients (APIs) Chemical synthesis of pharmaceutical active ingredients including paracetamol, oseltamivir, acetylcysteine, P-aminaphenol, antibiotics, antivirals, and anticoagulants. Atabay is the sole EMEA manufacturer of P-aminaphenol and paracetamol, supplying pharmaceutical companies worldwide.
• Human Pharmaceutical Products (Beşeri İlaçlar) Finished dosage form pharmaceuticals including antibiotics, syrups, sterile products, powder filling, tablets, capsules, and suppositories, with annual production capacity of approximately 250 million boxes. Sold through pharmacy and hospital channels across Turkey.
• Neoven 225 mg Kapsül First 100% domestic herbal medicinal product containing standardized Ruscus aculeatus extract, indicated for treatment of Chronic Venous Insufficiency and Hemorrhoidal Disease.
• Atabay BIO - Biotechnology & Vaccine Division Biotechnology division focused on biosimilar development and recombinant vaccine production using recombinant DNA technologies and microbial culture systems. Operates GMP-certified pilot-scale production facilities for clinical studies.
• Standardized Herbal Extracts Standardized botanical extraction products including Ruscus aculeatus and Hedera Helix extracts, developed through GMP-certified facilities in collaboration with TÜBİTAK MAM for Traditional Herbal Medicinal Products (THMP).
• Contract Manufacturing (Fason Üretim) Third-party contract manufacturing services utilizing Atabay's GMP-certified production facilities and pharmaceutical manufacturing expertise for partner companies.
• Sterile Manufacturing Sterile manufacturing facility with monthly capacity of 1 million units and annual capacity of 12 million vials, offering aseptic filling and vial production for sterile injectable pharmaceutical products.

Quantifiable outcome

• 300 million people worldwide use paracetamol produced at Atabay Gebze facility
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Istanbul Medipol UniversitycoreStrategic or Co-development Partner · 3 May 2020Collaboration for COVID-19 treatment drug development including Favipiravir synthesis, coordinated by Dr. Mustafa Güzel with 32-person research team achieving synthesis in 40 days
• TÜBİTAK MAMcoreStrategic or Co-development Partner · 1 March 2017Long-standing R&D collaboration with TÜBİTAK Marmara Research Center for pharmaceutical raw material development, biosimilar research, and Traditional Herbal Medicinal Products (THMP) including Ruscus aculeatus standardization project starting March 2017
• İzmir Biomedicine and Genome Center (İBG)coreStrategic or Co-development PartnerJoint projects on biotechnology research and development of new molecules using advanced molecular biology techniques
• Turkey's Top 10 UniversitiescoreStrategic or Co-development PartnerCollaborative R&D projects with leading Turkish universities including Gebze Technical University, Marmara University, and others for pharmaceutical development and technology transfer
• Start-up EcosystemminorStrategic or Co-development PartnerCollaboration with emerging biotech start-ups for innovative drug development and technology transfer support
• TÜSEBcoreStrategic or Co-development PartnerCollaboration with Turkish Health Institutes for vaccine development and health technology initiatives
• TAGEM (Tarım Araştırma ve Geliştirme Merkezi)minorStrategic or Co-development PartnerAgricultural research collaboration supporting the Traditional Herbal Medicinal Products (THMP) development project
• UNICEF TurkeyminorOthersSupport for UNICEF Turkey National Committee's work on children's rights, recognized with Golden Wing Award

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• DEVA Holding: Turkish pharmaceutical manufacturer with human pharma, veterinary, and API activities; one of Atabay's closest domestic rivals for finished generics and veterinary APIs.
• Euroapi: European-focused API manufacturer spun off from Sanofi; comparable business model as a standalone, EU-GMP-anchored API supplier competing for the same European de-risking demand.
• Abdi İbrahim: Turkey's largest domestic pharmaceutical manufacturer and a direct competitor across the same pharmacy/hospital channels in Turkey; both vertically integrated and focused on domestic production.
• Aurobindo Pharma: Indian API and finished-dosage manufacturer with comparable paracetamol, antiviral, and biosimilar capabilities; one of Atabay's principal global competitors on commodity APIs.
• Sandoz (Novartis): Global leader in generic pharmaceuticals and biosimilars spun off from Novartis; Atabay competes in the same generic-API and finished-dosage landscape with a comparable EU GMP certification-driven playbook.

Broad incumbents

• Dr. Reddy's Laboratories: Global generic and API powerhouse with broader therapeutic breadth and biosimilar portfolio; competes with Atabay on generic APIs and finished dosages across emerging markets.

Regional players

• Julphar (Gulf Pharmaceutical Industries): UAE-headquartered generic pharma player serving Middle East, Africa, and Asia; comparable business model focused on regional production for emerging markets and comparable regulatory positioning.
• Hikma Pharmaceuticals: MENA-rooted generics and injectables manufacturer with deep distribution in the Middle East and Africa—directly comparable to Atabay's regional export orientation in those geographies.
• Polpharma Biologic / Polpharma Group: Polish integrated generics and biologics manufacturer; comparable European-rooted vertically integrated pharma with API and biosimilar lines targeting CEE and EMEA markets.

Emerging players

• Biocon: Indian biopharmaceutical leader in biosimilars and fermentation-based APIs; comparable to Atabay BIO's strategic ambition to scale microbial biosimilar and vaccine production globally.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/atabayilac
• Instagraminstagram.com/atabayilac
• Xx.com/atabayas

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Atabay Chemical Industry